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Abstract
SAPHO syndrome, representing a constellation of synovitis, acne,
palmo-plantar pustulosis, hyperostosis, and osteitis, is now recog-
nized as a distinct medical entity: a reactive infectious osteitis.
Genetic, immunological, and bacterial mechanisms are implicated
in the development of the disease. Diagnostic problems may arise
due to non-complete manifestations of SAPHO: either acne and
arthritis or acne and anterior wall osteitis with an unclear pustulosis
history. The interventional study of Assmann et al. is a significant
addition to a long range of publications showing an association of
SAPHO with Propionibacterium acnes. Randomized control
studies are needed to confirm the effects of antibiotic therapy.
In the previous issue of Arthritis Research & Therapy, an
interventional study of patients with SAPHO (synovitis, acne,
pustulosis, hyperostosis, osteitis) syndrome, a skin-osteo-
articular inflammatory disease, showed positive bacterio-
logical cultures for Propionibacterium acnes in 14 of 21
(67%) patients who had undergone a needle biopsy of
osteitis lesions [1]. This is a significant addition to a long
range of publications showing an association of SAPHO with
P. acnes in 42% of patients (Table 1). The activity of SAPHO,
by assessment of skin disease, health assessment score,
radiological activity score, and osteitis lesions by magnetic
resonance imaging, decreased significantly after 16 weeks of
antibiotic therapy. The indices demonstrating disease activity
increased after discontinuation of the antibiotic treatment.
The relationship between infection and autoimmunity has
been increasingly defined over the last 20 years. In geneti-
cally susceptible individuals, environmental factors (mainly
infections) play a critical role in the pathogenesis of
autoimmune diseases. It is believed that infections contribute
to the maturation of the immune system from innate to
adoptive phases and that bacterial and viral infections are
arthritogenic stimulants leading to various rheumatic
conditions. Infectious agents may be the initial trigger of the
production of cross-reacting antibodies (molecular mimicry)
and may also induce the inflammatory ‘second hit’ mediated
by Toll-like receptors (TLRs) [2]. Molecular similarity of
microbial and host antigens (molecular mimicry) has recently
been proposed as a promoting factor for pathogen expansion
when microbial agents are not recognized as alien and not
completely eliminated [3].
Infectious agents isolated from SAPHO patients have merited
special attention for many years. Their possible etiological
role is supported by the pathogen isolation from different
sites: anterior chest wall, spine, synovial fluid, bone tissue,
and skin pustules. A range of pathogens have been found,
including Staphylococcus aureus, Hemophilus parainfluenzae,
actinomyces, and even Treponema pallidum [4]. P. acnes is a
much more frequent pathogen and plays a particular role. Of
note, speculation about contamination of bone biopsy
samples from skin seems to be inconsistent after standard
antiseptic procedures in the operation field. P. acnes is a
Gram-positive, motionless, non-spore-forming bacillus with
maximum growth in anaerobiosis. The microorganisms
involved in human disease have five biotypes, of which
biotypes I and III are the most frequently involved in the
etiopathogenesis of acne. They form part of the normal flora
of the oral cavity, large intestine, conjunctiva, external ear
conduit, and the skin, particularly the sebaceous follicles. In
1987, Trimble and colleagues [5] observed that intra-articular
injection of inactivated P. acnes in laboratory animals can
cause joint lesions and bone erosions.
A genetic background of P. acnes seems to be especially
relevant since its complete genome sequence has been
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detected and it clearly reveals numerous gene products
involved in the degradation of host molecules. This justifies
the ability of the germ to colonize and survive in human skin,
bone, and synovial fluid [6].
A genetic background in patients may be relevant given that
familial clustering has been reported [7]. A murine model
characterized by a spontaneous chronic recurrent multifocal
osteomyelitis related to a missense mutation of the gene for
proline-serine-threonine phosphatase interacting protein 2
(PSTPIP2) located on chromosome 18 also exists [8]. Some
similarities with two inherited genetic diseases, Majeed
syndrome and PAPA (pyogenic arthritis, pyoderma gangreno-
sum, and acne) syndrome, further support a genetic back-
ground [9]. There is growing evidence that an exaggerated
response to intestinal bacteria mediated by the NOD2/
CARD15 (nucleotide-binding oligomerization domain protein 2/
caspase recruitment domain 15) system in the inflammasome
(associated with Crohn disease) leading to a nuclear factor-
kappa-B overactivation may be involved in SAPHO syndrome
[10].
Multiple affected members who segregated a SAPHO
syndrome-like phenotype had neutrophil dysfunction and
reduced internal oxydant production [11]. That may explain
the inability of the innate system to eliminate the pathogen
from affected sites. This justifies long-term or permanent
antibiotic therapy.
It has been demonstrated that P. acnes may trigger a non-
specific activation of the complement system and cell-
mediated immunity in order to eliminate the germ-inducing
perpetuation of the inflammation. The ability of the germ to
persist in bone lesions in a form incompatible with culturing is
a possible explanation for its difficult isolation. The strong
humoral and cellular pro-inflammatory response has recently
been reported due to P. acnes with elevated interleukin (IL)-1,
IL-8, and IL-18 plasma levels and increased IL-8 and tumor
necrosis factor-alpha (TNF-α) production by purified poly-
morphonuclear cells [12]. P. acnes products have chemo-
attractant properties, and their immunomodulatory activity is
mediated by TLR9 [13].
This justifies long-term or permanent anti-inflammatory
therapy. SAPHO syndrome is commonly refractory to non-
steroidal anti-inflammatory drugs, glucocorticoids, and disease-
modifying anti-rheumatic drugs. Intravenous biphosphonate
pamidronate with its strong anti-inflammatory and lympho-
penic effect proved to be effective in achieving long-term
remission of SAPHO syndrome [14].
At least six uncontrolled studies showed efficacy of antibiotic
therapy (azithromycin, doxycycline, sulfamethoxazole/trimetoprim)
in SAPHO syndrome. Long-term antibiotic therapy is recom-
mended in most cases. Some patients may respond to
repeated 6-week to 3-month courses with 1- to 2-month
intervals in order to prevent resistance to antibiotics.
Anti-TNF-α therapy proved to be effective against osteo-
articular manifestations of SAPHO syndrome, but deteriora-
tion of skin pustulosis was observed in some patients [15].
Combined therapy, including anti-TNF medication and an
antibiotic, may be a reasonable solution.
SAPHO syndrome, representing a constellation of synovitis,
acne, palmo-plantar pustulosis, hyperostosis, and osteitis, is
now recognized as a distinct medical entity: a reactive
infectious osteitis. Genetic, immunological, and bacterial
mechanisms are implicated in the development of the
disease. Diagnostic problems may arise due to incomplete
manifestations of SAPHO: either acne and arthritis or acne
and anterior wall osteitis with an unclear pustulosis history.
The physician needs to make a careful inquiry about a past
history of pustulosis. An early bone scanogram is strongly
advised in patients with anterior chest pain and a suspicion of
SAPHO syndrome. Due to the remitting course, decreased
disease activity might be related to the natural course of the
disease and not to the efficacy of the antibiotic therapy. Thus,
randomized placebo control studies are needed to document
the effects of antibiotic therapy. Further trials are needed to
create a model of SAPHO disease using P. acnes transfer to
healthy animals. Mechanisms of ineffective host responses for
neutralizing and eliminating P. acnes should also be
investigated.
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Table 1
Positive findings of Propionibacterium acnes in bone lesions
in cases of SAPHO syndrome
Propionibacterium 
Authors Investigated acnes-positive
Sherusan et al. [16] 1982 1 1
Collert and Isacson [17] 1982 1 1
King et al. [18] 1987 7 1
Edlund et al. [19] 1988 15 7
Gerster et al. [20] 1990 1 1
Kotilainen et al. [21] 1996 1 1
Reith et al. [22] 1996 8 2
Hayem [10] 1999 15 1
Kirchhoff et al. [23] 2003 14 8
Colina et al. [14] 2007 6 1
Assmann et al. [1] 2009 21 14
Total 90 38 (42%)
SAPHO, synovitis, acne, pustulosis, hyperostosis, osteitis.References
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